Drug Trial Radar · NCT07521748
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Dec 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Nanjing Reju Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants.RC017 is a small-molecule drug, being developed as a novel therapeutic treatment for patients with Dry Eye Disease (DED) . This study aims to evaluate the safety, tolerability and pharmacokinetics of RC017 after Single and Multiple Doses.
Conditions
- Dry Eye
Interventions
RC017 Ophthalmic OintmentDrug
Participants were randomly assigned to the 3 dose groups
RC017 Ophthalmic Ointment placeboDrug
Match to RC017 Ophthalmic Ointment dose groups
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of Treatment-emergent adverse events (TEAEs)Time frame: Day1 to Day 21
- The severity of Treatment-emergent adverse events (TEAEs)Time frame: Day 1-Day 21
- The incidence of Serious adverse events (SAEs)Time frame: Day 1-Day 21
- The severity of Serious adverse events (SAEs)Time frame: Day 1-Day 21
- Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parametersTime frame: Day 1-Day 21
- Number of participants with abnormal clinically significant clinical laboratory resultsTime frame: Day 1- Day 21
- Number of patients with abnormal clinically significant results from physical examinationTime frame: Day 1-Day 21
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.